Results 1 to 10 of about 19,009 (196)

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report

open access: yesCardio-Oncology, 2023
Background Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML).
Ankur Sheel   +5 more
doaj   +2 more sources

Absence of early platelet increment in healthy mice during decitabine treatment

open access: yesScientific Reports, 2022
Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on
Juliane Baumann   +4 more
doaj   +2 more sources

DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia

open access: yesClinical Epigenetics, 2023
Background Despite its inconsistent response rate, decitabine, a demethylating agent, is often used as a non-intensive alternative therapeutic agent for acute myeloid leukemia (AML). It has been reported that relapsed/refractory AML patients with t(8;21)
Shujiao He   +6 more
doaj   +1 more source

Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction. [PDF]

open access: yesPLoS ONE, 2014
Efficient ex vivo transduction of hematopoietic stem cells (HSCs) is encumbered by differentiation which reduces engraftment. We hypothesized that inhibiting DNA methyltransferase with decitabine would block differentiation of transduced CD34+ cells ...
Naoya Uchida   +4 more
doaj   +1 more source

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation

open access: yesFrontiers in Cell and Developmental Biology, 2021
BackgroundCD4+ T cells play multiple roles in controlling tumor growth and increasing IFN-γ+ T-helper 1 cell population could promote cell-mediated anti-tumor immune response.
Xiang Li   +9 more
doaj   +1 more source

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes

open access: yesCells, 2021
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease characterized by inefficient hematopoiesis and the potential development of acute leukemia.
Seungyoun Kim   +6 more
doaj   +1 more source

Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas

open access: yesClinical Epigenetics, 2023
Background Targeting the epigenome of cancerous diseases represents an innovative approach, and the DNA methylation inhibitor decitabine is recommended for the treatment of hematological malignancies.
Zijiao Tang, Lu Liu, Jürgen Borlak
doaj   +1 more source

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

open access: yesCancer Medicine, 2023
Background There is an urgent need for effective treatment of patients with relapsed/refractory diffuse large B‐cell lymphoma (R/R‐DLBCL). This trial investigated the efficacy of decitabine in combination with rituximab, cisplatin, cytarabine ...
Xiaoshuang Kong   +15 more
doaj   +1 more source

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

open access: yesJournal for ImmunoTherapy of Cancer, 2021
Background Programmed death-1 (PD-1) blockade monotherapy induced durable remission in a subset of patients with relapsed/refractory classical Hodgkin lymphoma (cHL). We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating
Weidong Han   +7 more
doaj   +1 more source

Abnormal Ferroptosis in Myelodysplastic Syndrome

open access: yesFrontiers in Oncology, 2020
BackgroundFerroptosis is a form of iron-dependent non-apoptotic cell death, with characteristics of loss of the activity of the lipid repair enzyme, glutathione (GSH) peroxidase 4 (GPX4), and accumulation of lethal reactive lipid oxygen species.
Qi Lv   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy